Publication date: Jul 06, 2025
The PFS and OS were analyzed using KaplanMeier survival curves. The ORR was determined using both RECIST v. 1.1 (Response Evaluation Criteria in Solid Tumors) and iRECIST (Immune Response Evaluation Criteria in Solid Tumors). Baseline blood markers were evaluated as possible predictive or prognostic indicators. Group comparisons were made with the log-rank test.
| Concepts | Keywords |
|---|---|
| Dehydrogenase | Advanced |
| Immunotherapy | Ci |
| June | Com |
| Onlinelibrary | Elevated |
| Hr | |
| Individuals | |
| Ldh | |
| Line | |
| Melanoma | |
| Multivariate | |
| Pfs | |
| Pretreatment | |
| Receiving | |
| Sii | |
| Survival |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | inflammation |
| disease | MESH | Tumors |
| drug | DRUGBANK | Coenzyme M |
| pathway | KEGG | Melanoma |
| disease | MESH | Melanoma |
Original Article
(Visited 6 times, 1 visits today)